Autopsy report · NCT00302341
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
Cause of deathFunding or business, also safety
“FDA Clinical Hold as of 12/21/07 due to safety concerns”
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 7 months before it stopped.
- 48 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Immtech Pharmaceuticals, Inc
- Sponsor type
- Industry
- Conditions
- Pneumonia, Interstitial Plasma Cell; Pneumocystis Carinii Pneumonia; Pneumonia, Pneumocystis Carinii; HIV Infections
- Interventions
- Pafuramidine maleate (DB289); Trimethoprim-Sulfamethoxazole (TMP-SMX)
- Participants
- 48
- Sites
- 7
- Countries
- United States
Trials that died the same way
- Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
“FDA Clinical Hold” - A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
“Full clinical hold from FDA” - Safety of SP-420 in the Treatment of Transfusional Iron Overload
“Study is on hold by FDA in the US.” - AZD1222 Vaccine for the Prevention of COVID-19
“The study was put on hold in September 2020 due to a safety concern in another trial but never restarted. In the meantime our clinical development program now includes a similar study with a different design, which we prefer to complete now.” - MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
“FDA hold on the project”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.